Pay in 4 interest-free payments of $6.15 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
What services do you offer
Ive been a PI on several GLP-1 trials for the last 15 years, but their current marketed indications are only from the last two to three years. The dual agonist GIP + GLP-1 (tirzepatide) and high-dose semaglutide are approved specifically for non-diabetic obesity: BMI above 25 with one comorbidity, or BMI above 30 with no comorbidities or diabetes
[1] [3] This is particularly relevant for post-bariatric patients, who may already have altered biliary physiology
This is where FuturHealth stands outdelivering affordable, prescription-grade GLP-1 semaglutide medication directly to qualified individuals through a telehealth-based weight loss program
